Key result
A 1 standard deviation increase in serially measured log[hs-cTnT] was associated with a 61% increased risk of cardiovascular mortality and recurrent ACS (HR 1.61; 95% CI 1.02-2.44; P=0.045).
Why the study?
Evidence regarding the role of serial biomarker measurements for risk assessment in post-ACS patients is limited.
Do serially measured hs-cTnT, NT-proBNP, hs-CRP, and GDF-15 predict cardiovascular mortality and recurrent ACS in post-ACS patients?
Observational (n=844)
Yes
Do serially measured hs-cTnT, NT-proBNP, hs-CRP, and GDF-15 predict cardiovascular mortality and recurrent ACS in post-ACS patients?
Hazard Ratio: 1.61 (95% CI 1.02–2.44)
p-value: p=0.045
Serial hs-cTnT monitoring may refine post-ACS risk stratification; hypothesis-generating before guiding interventions.
AIMS: Evidence regarding the role of serial measurements of biomarkers for risk assessment in post-acute coronary syndrome (ACS) patients is limited. The aim was to explore the prognostic value of four, serially measured biomarkers in a large, real-world cohort of post-ACS patients. METHODS AND RESULTS: BIOMArCS is a prospective, multi-centre, observational study in 844 post-ACS patients in whom 12 218 blood samples (median 17 per patient) were obtained during 1-year follow-up. The longitudinal patterns of high-sensitivity cardiac troponin T (hs-cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and growth differentiation factor 15 (GDF-15) were analysed in relation to the primary endpoint (PE) of cardiovascular mortality and recurrent ACS using multivariable joint models. Median age was 63 years, 78% were men and the PE was reached by 45 patients. The average biomarker levels were systematically higher in PE compared with PE-free patients. After adjustment for 6-month post-discharge Global Registry of Acute Coronary Events score, 1 standard deviation increase in log[hs-cTnT] was associated with a 61% increased risk of the PE [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.02-2.44, P = 0.045], while for log[GDF-15] this was 81% (HR 1.81, 95% CI 1.28-2.70, P = 0.001). These associations remained significant after multivariable adjustment, while NT-proBNP and hs-CRP were not. Furthermore, GDF-15 level showed an increasing trend prior to the PE (Structured Graphical Abstract). CONCLUSION: Longitudinally measured hs-cTnT and GDF-15 concentrations provide prognostic value in the risk assessment of clinically stabilized patients post-ACS. CLINICAL TRIAL REGISTRATION: The Netherlands Trial Register. Currently available at URL https://trialsearch.who.int/; Unique Identifiers: NTR1698 and NTR1106.
No takes yet. Share an insight, caveat, or question.
Gürgöze et al. (2023) conducted an observational in post-acute coronary syndrome (ACS) (n=844). Serial measurements of hs-cTnT and GDF-15 was evaluated on Cardiovascular mortality and recurrent ACS (HR 1.61, 95% CI 1.02-2.44, p=0.045). A 1 standard deviation increase in serially measured log[hs-cTnT] was associated with a 61% increased risk of cardiovascular mortality and recurrent ACS (HR 1.61; 95% CI 1.02-2.44; P=0.045).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: